AbCellera Biologics News - ABCL

Company Name	Stock Ticker Symbol	Market	Type
AbCellera Biologics Inc	ABCL	NASDAQ	Common Stock

	Price Change	Change Percent	Stock Price	Last Traded
	0.145	3.99%	3.775	10:24:38

Open Price	Low Price	High Price	Close Price	Prev Close
3.69	3.65	3.785		3.63

more quote information »

Recent News

Date	Time	Source	Heading
4/08/2024	12:05	BW	AbCellera Presents Data on T-Cell Engagers Against Four..
4/03/2024	16:05	BW	AbCellera to Report First Quarter 2024 Financial Results on..
3/19/2024	16:05	BW	AbCellera to Present at the Bloom Burton Healthcare..
3/11/2024	09:00	BW	AbCellera to Collaborate with Biogen to Discover Therapeutic..
3/05/2024	16:30	BW	AbCellera Announces Four Presentations on T-Cell Engagers at..
2/27/2024	14:12	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
2/23/2024	16:49	EDGAR2	Form 8-K - Current report
2/23/2024	16:30	BW	AbCellera Announces Resignation of Board Member
2/22/2024	20:15	BW	AbCellera to Present at Upcoming Investor Conferences in..
2/20/2024	16:49	EDGAR2	Form S-8 - Securities to be offered to employees in employee..
2/20/2024	16:27	EDGAR2	Form 8-K - Current report
2/20/2024	16:05	BW	AbCellera Reports Full Year 2023 Business Results
1/23/2024	16:05	BW	AbCellera to Report Full Year 2023 Financial Results on..
1/16/2024	18:23	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
1/16/2024	18:21	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
1/16/2024	18:18	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
1/16/2024	18:14	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
12/20/2023	16:05	BW	AbCellera to Present at the 42nd Annual J.P. Morgan..
12/19/2023	18:08	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
11/28/2023	17:28	EDGAR2	Form 8-K - Current report
11/27/2023	16:45	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
11/16/2023	16:05	BW	AbCellera to Present at the Piper Sandler 35th Annual..
11/08/2023	15:29	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
11/03/2023	12:05	BW	AbCellera Presents New Data on Two T-Cell Engager Programs..
11/02/2023	16:13	EDGAR2	Form 8-K - Current report
11/02/2023	16:05	BW	AbCellera Reports Q3 2023 Business Results
11/01/2023	16:05	GLOBE	Prelude Therapeutics and AbCellera Enter Partnership to..
10/31/2023	16:05	BW	AbCellera to Present at the Jefferies London Healthcare..
10/11/2023	16:05	BW	AbCellera to Report Third Quarter 2023 Financial Results on..
9/27/2023	09:00	BW	AbCellera Announces Two T-Cell Engager Presentations at SITC..
9/20/2023	17:02	BW	AbCellera Expands Multi-Target Antibody Discovery..
9/20/2023	09:00	BW	AbCellera Expands Multi-Target Antibody Discovery..
9/14/2023	16:38	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
9/13/2023	09:00	BW	AbCellera Announces Collaboration with Incyte to Accelerate..
8/25/2023	13:57	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
8/03/2023	16:33	EDGAR2	Form 10-Q - Quarterly report [Sections 13 or 15(d)]
8/03/2023	16:15	EDGAR2	Form 8-K - Current report
8/03/2023	16:05	BW	AbCellera Reports Q2 2023 Business Results
7/24/2023	16:05	BW	AbCellera Announces that the U.S. Patent Trial and Appeal..
7/06/2023	16:05	BW	AbCellera to Report Second Quarter 2023 Financial Results on..
5/29/2023	16:05	BW	AbCellera to Present at the Goldman Sachs 44th Annual Global..
5/24/2023	13:10	BW	AbCellera Partners with the Governments of Canada and..
5/04/2023	16:05	BW	AbCellera Reports Q1 2023 Business Results